# TMDX — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-06-29. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 6.8 · Fundamentals 7.5 · Technicals 3.5 · Growth 8 · Risk 7.5

## Summary

TransMedics has the rare combination of 30% top-line growth, 27% net margins and 45% ROE, but the stock has been cut nearly in half YTD (-43.7%) on Stifel's cautious note and a $722K insider sale, leaving it at ~$68 vs. analyst targets near $119. The fundamentals remain compelling for a category-defining medical device platform, but Q1 2026 showed clear margin compression and FCF turned negative, so this is a high-conviction-but-volatile setup that warrants accumulation rather than chasing.

## Price targets (12-month horizon)

- Bear: $52.00
- Base: $95.00
- Bull: $130.00

## News context

The actionable news is squarely bearish in the near-term: Stifel maintained a Hold with a $80 PT (June 18) and an insider sold $722K of stock (June 24), which together appear to have triggered the ~12% single-day drop visible on the 1h chart. Management has reportedly rebutted Stifel's commentary but has not issued a formal public statement, leaving an information vacuum into the May 5 earnings print (per snapshot data — date appears stale, next earnings is the key catalyst). The Simply Wall St. piece (June 6) reinforces the bull case around the OCS platform's role in transforming organ transplant economics, which remains the structural thesis. Crypto/macro headlines in the broader feed are irrelevant to TMDX.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/tmdx-ai-stock-forecast-d221339cc0775eff92544b94fcf194fa
- AI-generated; model outputs can be wrong. Not financial advice.